Last reviewed · How we verify
Wuhan BravoVax Co., Ltd. — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Recombinant Zoster Vaccine | Recombinant Zoster Vaccine | marketed | ||||
| Zoster Vaccine Recombinant, Adjuvanted | Zoster Vaccine Recombinant, Adjuvanted | marketed | Recombinant subunit vaccine with adjuvant | Varicella-zoster virus glycoprotein E (gE) | Immunology / Infectious Disease |
Therapeutic area mix
- Immunology / Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- GlaxoSmithKline · 1 shared drug class
- Wuerzburg University Hospital · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Wuhan BravoVax Co., Ltd.:
- Wuhan BravoVax Co., Ltd. pipeline updates — RSS
- Wuhan BravoVax Co., Ltd. pipeline updates — Atom
- Wuhan BravoVax Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Wuhan BravoVax Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/wuhan-bravovax-co-ltd. Accessed 2026-05-18.